tiprankstipranks
Advertisement
Advertisement
ResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats
PremiumCompany AnnouncementsResMed Reaffirms 2025 Risk Profile: No Material Changes to Previously Disclosed Threats
2M ago
ResMed Inc Earnings Call Shows Profitable Growth Momentum
Premium
Company Announcements
ResMed Inc Earnings Call Shows Profitable Growth Momentum
2M ago
ResMed price target raised to $314 from $311 at RBC Capital
Premium
The Fly
ResMed price target raised to $314 from $311 at RBC Capital
2M ago
ResMed Announces Dividend and Strong Quarterly Earnings Growth
PremiumCompany AnnouncementsResMed Announces Dividend and Strong Quarterly Earnings Growth
2M ago
ResMed reports Q2 EPS $2.81, consensus $2.72
Premium
The Fly
ResMed reports Q2 EPS $2.81, consensus $2.72
2M ago
Is RMD a Buy, Before Earnings?
Premium
Pre-Earnings
Is RMD a Buy, Before Earnings?
2M ago
ResMed removed from APAC Conviction List at Goldman Sachs
PremiumThe FlyResMed removed from APAC Conviction List at Goldman Sachs
4M ago
ResMed Streamlines Governance at Annual Meeting
Premium
Company Announcements
ResMed Streamlines Governance at Annual Meeting
4M ago
ResMed price target lowered to $300 from $320 at Baird
Premium
The Fly
ResMed price target lowered to $300 from $320 at Baird
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100